EPT

Emergence

EPT's origins are unrecorded — no synthesist, laboratory, or date of first preparation appears in the accessible literature. The compound is absent from Alexander and Ann Shulgin's TiHKAL (1997), the canonical reference for psychedelic tryptamines.^[2] It first surfaced on research chemical markets around 2016, with the earliest user reports describing insufflated and smoked self-experiments at 30–50 mg.^[9]

Published research

The scientific literature on EPT consists of two papers. Chadeayne and colleagues reported the crystal structure of EPT hydrofumarate in 2020, providing the only primary-source structural characterization.^[8] Bergh and colleagues followed in 2024 with an in vitro metabolite identification using human liver microsomes and documented a human postmortem case in which EPT or 4-hydroxy-EPT was suspected as a contributing substance.^[6]

Forensic detection

EPT was identified in six seized illicit products in Japan between 2017 and 2019, alongside related compounds including 4-hydroxy-EPT.^[3] It has since been incorporated into validated forensic extraction methods for tryptamine analogs in whole blood.^[10]

Structural class

EPT belongs to the substituted tryptamine family — indoleamine derivatives bearing an aminoethyl chain at the indole 3-position. It is a mixed N,N-dialkyl tryptamine, carrying one ethyl and one propyl group on the terminal amine nitrogen. This asymmetric substitution places EPT structurally between DET (both chains C₂) and DPT (both chains C₃). The IUPAC name is N-ethyl-N-[2-(1H-indol-3-yl)ethyl]propan-1-amine.

Molecular properties

The tryptamine core consists of a bicyclic indole ring system (fused benzene and pyrrole rings) with a 2-aminoethyl side chain at C-3. The nitrogen bears ethyl (C₂H₅) and propyl (C₃H₇) substituents, yielding a tertiary amine.

Stereochemistry

EPT contains no chirality centers and exists as a single achiral species. Crystal structure data confirm conformational flexibility of the N-ethyl chain, which exhibits positional disorder with equal occupancy for each orientation in the solid state.^[8]

Solid-state characterization

Chadeayne and colleagues crystallized EPT as its hydrofumarate salt and solved the structure by single-crystal X-ray diffraction.^[8] The extended structure consists of tryptammonium cations and hydrofumarate anions linked by hydrogen bonds into infinite two-dimensional networks. The near-planarity of the indole ring (mean atomic deviation 0.008 Å) confirms aromatic delocalization across the bicyclic system.

Physical properties

No published data exist for the melting point, solubility, or stability of EPT in either free-base or salt form. The free base is expected to be a waxy solid or oil at room temperature, consistent with other dialkyl tryptamines of comparable molecular weight.inferred Degradation pathways have not been characterized.

Mechanism of action

No binding data exist for EPT at any receptor. All mechanistic understanding is inferred from DPT and the broader dialkyl tryptamine class.

EPT is presumed to act primarily as a partial agonist at 5-HT₂A receptors, the principal target mediating psychedelic effects in tryptamines.^[12] DPT fully substitutes for LSD and psilocybin in animal discrimination studies, an effect blocked entirely by selective 5-HT₂A antagonism.^[1][13] DPT also engages 5-HT₁A receptors,^[14] which modulate the hallucinogenic response;^[15] EPT likely shares this dual profile.inferred

The size of the nitrogen substituents influences how tryptamines interact with serotonin transporters and shifts the balance between receptor targets.^[16][17][12] EPT's asymmetric ethyl/propyl substitution falls between DET and DPT in steric demand, but no measurements confirm where it lands.

Pharmacokinetics

No human pharmacokinetic parameters have been determined for EPT. Primary clearance is expected via MAO-A (MAO-A), the dominant metabolic pathway for short-chain dialkyl tryptamines.^[18]

In vitro metabolite characterization using human liver microsomes identified three major pathways: indole ring hydroxylation (the primary route), N-dealkylation, and carbonylation.^[6] These pathways are consistent with tryptamine class metabolism but have not been confirmed in vivo.

Insufflation, the primary route of administration, bypasses first-pass liver metabolism. This likely explains EPT's activity at moderate insufflated doses without requiring an monoamine oxidase inhibitor.

No neuroimaging, electrophysiology, or neuroplasticity data have been published for EPT. All neural mechanisms described below are inferred from the serotonergic psychedelic class and applied to EPT on the basis of its presumed 5-HT₂A agonism.inferred

Where it acts

Serotonergic psychedelics engaging 5-HT₂A receptors on cortical pyramidal neurons disrupt the default mode network (the brain system supporting self-referential thought), reduce thalamic filtering of sensory information, and increase communication between normally segregated brain regions. These effects produce the characteristic psychedelic signature: ego dissolution, visual hallucinogenesis, and expanded associative thinking.

EPT's reported cognitive clarity during strong visual effects raises the question of whether its receptor profile preserves prefrontal executive function while disrupting visual cortex processing — a pattern not typically described for DPT or DMT.

Theoretical frameworks

The REBUS model proposes that psychedelics loosen the brain's high-level expectations, allowing sensory input to reshape perception from the bottom up. EPT's combination of visual intensity with analytical lucidity could represent a partial form of this relaxation — visual priors disrupted while metacognitive monitoring remains intact.

Tryptamine psychedelics have also been identified as psychoplastogens — compounds promoting rapid structural changes in neurons. Whether EPT shares this property is unknown, though its structural similarity to DPT and DMT (both confirmed psychoplastogens in vitro) suggests probable activity.inferred

Toxicity

No controlled toxicology studies exist for EPT. The lethal dose has not been determined in any species, and the therapeutic index is unknown.safety citation needed

One human death has been documented in which EPT or 4-hydroxy-EPT was suspected as a contributing substance.^[6] The circumstances, concurrent substances, and whether EPT was causally implicated have not been published. This case neither establishes nor rules out EPT-specific lethality.

Classical serotonergic psychedelics are generally considered to have low acute physical toxicity relative to their psychoactive dose.^[20][21] Morbidity associated with novel tryptamines is likely underestimated, driven by psychological adverse effects, polydrug contexts, and behavioral risks during intoxication.^[20]

Psychedelic-related deaths, while rare, do occur — often involving polydrug use or high-risk behavior.^[22] Cardiovascular effects including vasoconstriction and increased heart rate are documented for the tryptamine class but have not been measured for EPT.inferred

Psychological risks

The primary risks of EPT use are psychological. Reported adverse effects include acute anxiety and disorientation, particularly at higher doses.^[19] Higher doses amplify the risk of overwhelming experiences, thought loops, paranoia, and ego dissolution.

Psychological state strongly influences experience quality — user reports specifically identify set and setting as primary determinants of outcome.^[19] No data exist on EPT and persisting perceptual changes, psychosis precipitation, or psychiatric destabilization. By class analogy, individuals with a personal or family history of psychotic spectrum disorders face elevated risk.inferred

Tolerance and dependence

No tolerance or dependence data specific to EPT have been published.

Repeated use of serotonin 2A receptor agonists produces rapid downregulation.^[7] Tryptamine hallucinogens develop somewhat less tolerance than phenethylamine hallucinogens in animal models.^[23] Community estimates place tolerance onset immediately after use, with a 3-day half-life and 7-day full reset, with cross-tolerance to other serotonergic psychedelics.^[2] These are standard class-level estimates, not EPT-specific measurements.

Classical serotonergic psychedelics have low abuse potential and low abuse liability.^[5] They do not produce physical dependence or withdrawal syndromes.

Drug interactions

No interaction data specific to EPT exist. All assessments below are inferred from tryptamine class pharmacology.

Contraindications

No substance-specific contraindication data exist for EPT. All contraindications are inferred from serotonergic psychedelic class pharmacology.inferred

Concurrent MAO inhibitor use, personal history of psychotic spectrum disorders, and lithium therapy represent the most serious concerns. Cardiovascular disease, bipolar disorder, severe anxiety disorders, concurrent SSRI/SNRI use, and pregnancy are additional risk factors. The absence of reproductive toxicity data makes EPT contraindicated in pregnancy by default.

EPT occupies a varied legal position across jurisdictions. As a tryptamine absent from international scheduling conventions, its status ranges from explicitly controlled to unscheduled but potentially prosecutable under structural analog legislation.^[26][2]

Analog act considerations

In the United States, the Federal Analogue Act extends Schedule I/II controls to substances substantially similar in chemical structure or pharmacological effect to listed compounds, when intended for human consumption. EPT's structural relationship to DMT (Schedule I) — differing only in the N-alkyl substituents — establishes a plausible basis for prosecution. Application is determined case-by-case and depends on judicial interpretation of substantial similarity.